Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | COMT | P21964 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3447723 | 0.81 | CYP1A2 (0.54) | CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL332440 | 0.79 | CYP1A2 (0.53) | CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL16826278 | 0.79 | CYP3A4 (0.53) | CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL19356930 | 0.79 | CYP1A2 (0.53) | CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL14938176 | 0.79 | CYP1A2 (0.53) | CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL3489735 | 0.79 | CYP1A2 (0.53) | CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL14938282 | 0.79 | PORCN (0.55) | CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL17369090 | 0.79 | CYP1A2 (0.53) | CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL21258381 | 0.79 | CYP1A2 (0.53) | CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL4133270 | 0.78 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119371412-A | CYP11B2 inhibitor compound, pharmaceutical composition and application thereof | 长春金赛药业有限责任公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2023244788-A9 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023244788-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| WO-2008065493-A1 | PYRAZOLE ANALOGS | PFIZER PRODUCTS INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008065493-A1 | PYRAZOLE ANALOGS | PFIZER PRODUCTS INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20080125474-A1 | Pyrazole Analogs | PFIZER INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125474-A1 | Pyrazole Analogs | PFIZER INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125474-A1 | Pyrazole Analogs | PFIZER INC. | 2008-05-29 | — | — | US | disclosed |
| CN-1582287-A | Thiophenylthiopyrane dioxides as MMP or TNF-alpha inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-02-16 | — | — | CN | disclosed |
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-30 | — | — | US | disclosed |
| EP-1423386-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003022842-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-20 | — | — | WO | disclosed |
| WO-1994015920-A1 | BENZANILIDE DERIVATIVES AS 5-HT1D-ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1994-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | TNF, MMP9, MMP1 | CYP1A2 1151/4885CYP3A4 1806/4885CYP2D6 1700/4885 |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | CYP1A2 3484/4885CYP3A4 4562/4885CYP2D6 4316/4885 |
| US-20080125474-A1 | Pyrazole Analogs | IL33, CFTR, HRH1 | CYP1A2 39/4885CYP3A4 28/4885CYP2D6 36/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | CYP1A2 3484/4885CYP3A4 4562/4885CYP2D6 4316/4885 |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, JAK1, JAK3 | CYP1A2 3726/4885CYP3A4 4028/4885CYP2D6 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.